NASDAQ:VKTX - Viking Therapeutics Stock Price, Price Target & More

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Viking Therapeutics Inc (NASDAQ:VKTX) issued its earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.10) EPS for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.02. View Viking Therapeutics' Earnings History.

Viking Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Viking Therapeutics.

7 equities research analysts have issued twelve-month price objectives for Viking Therapeutics' stock. Their forecasts range from $13.00 to $15.00. On average, they expect Viking Therapeutics' stock price to reach $14.3333 in the next year. This suggests a possible upside of 31.3% from the stock's current price. View Analyst Ratings for Viking Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Viking Therapeutics saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 9,698,446 shares, an increase of 57.6% from the June 15th total of 6,154,705 shares. Based on an average daily volume of 3,578,336 shares, the days-to-cover ratio is presently 2.7 days. Currently, 19.3% of the company's stock are short sold. View Viking Therapeutics' Current Options Chain.

Some companies that are related to Viking Therapeutics include Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Endo International (ENDP), Spectrum Pharmaceuticals (SPPI), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), Arena Pharmaceuticals (ARNA), TESARO (TSRO), Global Blood Therapeutics (GBT), ACADIA Pharmaceuticals (ACAD), Zogenix (ZGNX), Myokardia (MYOK) and Puma Biotechnology (PBYI).

(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

News headlines about VKTX stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viking Therapeutics earned a media sentiment score of 0.24 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.34 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Viking Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.10%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Matthew W Foehr and Michael Morneau. View Institutional Ownership Trends for Viking Therapeutics.

VKTX stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have bought Viking Therapeutics stock in the last two years include J Matthew Singleton, Lawson Macartney and Matthew W Foehr. View Insider Buying and Selling for Viking Therapeutics.

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of VKTX stock can currently be purchased for approximately $10.92.

Viking Therapeutics has a market capitalization of $662.33 million. The biotechnology company earns $-20,570,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Viking Therapeutics employs 14 workers across the globe.

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]